data

Clarivate Unveils the 2025 Journal Citation Reports

50th Anniversary Year Sees Strengthened Focus on Research Integrity LONDON, June 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider…

8 months ago

Mobile industry emissions down 8%, but pace must double to hit net zero

LONDON, June 18, 2025 /PRNewswire/ -- The mobile industry's operational emissions fell by 8% between 2019 and 2023, even as…

8 months ago

The Block Announces Strategic Leadership Evolution as Leading Digital Asset News Platform Enters Next Growth Phase

Larry Cermak transitions to President role to focus on research and product innovation; Kaleb Jessee promoted to CEO NEW YORK,…

8 months ago

Arcontech Excelerator. A performant, stress-free alternative to migrating to LSEG Workspace Excel Add-in

LONDON, June 17, 2025 /PRNewswire/ -- For the thousands of financial professionals who rely on the established functionality and market sheets…

8 months ago

Nokia launches Autonomous Network Fabric to help customers accelerate network automation

Press releaseNokia launches Autonomous Network Fabric to help customers accelerate network automation Nokia Autonomous Network Fabric brings together all the…

8 months ago

adidas Launches F50 SPARKFUSION A Boot Built by and for Womens Football Players

Designed using adidas’ biggest ever study into the boot requirements of women in football, F50 SPARKFUSION supports the specific performance…

8 months ago

Airsys Receives Frost & Sullivan’s 2025 North America Company of the Year Recognition for Excellence in Data Center Thermal Management

The recognition showcases Airsys's groundbreaking advancements in energy-efficient cooling, thermal innovation, and sustainability for high-density data centers SAN ANTONIO, June…

8 months ago

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

8 months ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

8 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

June 14, 2025 10:48 ET  | Source: Celldex Therapeutics, Inc. 77% of patients (150 mg Q4W) treated with barzolvolimab who…

8 months ago